Pfizer and GSK spearhead development of promising RSV vaccines
Vaccines for RSV from GSK and Pfizer to be analysed by a panel of experts with a view to informing a decision from the US FDA on their approval.
The next stage in an exciting head-to-head between Pfizer and GSK to develop the first vaccine for respiratory syncytial virus (RSV) will take place this week as a panel of experts for the US FDA come to assess the vaccines.
RSV is common cold-like respiratory virus that is responsible for the deaths of around 14,000 older adults in the US every year. A vaccine that could protect the most vulnerable from this virus would be a big step forward.
For GSK and Pfizer it would also mean securing their place in the market, with a return of up to $10 billion according to recent estimates.
The vaccine, for which approval is sought for use in adults aged 60 and over, will come under scrutiny from a panel of experts, who will then provide an independent report for the FDA to consider, eventually deciding on final approval by May of this year. If all goes to plan then the vaccine would be available for patients in time for the seasonal increase in virus prevalence in winter, providing timely protection.
Research into RSV has been ongoing since the 1960s, so to finally have a breakthrough in the development of a vaccine is a real win for the industry and a credit to the recent advances in the fields of vaccine development and infectious diseases.
"RSV is the last of the great big respiratory viruses that afflict our population on an annual basis," stated William Schaffner of Vanderbilt University Medical Centre.
Other leaders in the field, Merck, Moderna and Johnson & Johnson have also developed RSV vaccines, which are currently undergoing clinical trials.
GSK and Pfizer have been leading the charge after initial results from late-stage studies conducted by the two companies demonstrated that their vaccines prevented the occurrence of respiratory disease after infection by RSV.
The key results were as follows: GSK's vaccine was 82.6% effective in preventing lower respiratory tract disease in people of over 60 years old, and 94.1% effective in preventing severe disease in this population.
The vaccine from Pfizer was 66.7% effective in preventing lower respiratory tract disease that occurs with over two symptoms, and 85.7% effective against illness with over three symptoms.
The results are extremely promising and a favourable outcome from the panel assessment is expected with a view to approving the vaccines in the future.
Related News
-
News On Track at Pharmapack 2024 - The Track Sponsor interview: BD Pharmaceuticals
January 2024 brings both a new year and Europe’s leading packaging and drug delivery event. Bringing the world’s experts in pharmaceutical packaging together in Paris, France, Pharmapack 2024 brings exciting opportunities to learn and colla... -
News Patients vs Pharma – who will the Inflation Reduction Act affect the most?
The Inflation Reduction Act brought in by the Biden administration in 2022 aims to give better and more equitable access to healthcare in the USA. However, pharma companies are now concerned about the other potential costs of such legislation. -
News Roche breaks into the obesity drug market with the acquisition of Carmot Therapeutics
In a bid to diversify their therapeutic offerings, Roche takes over Carmot Therapeutics in $2.7 billion deal, with one obesity drug spearheading the venture into the field as they prep for a Phase II in-human trial. -
News Biden backs Cold-War measures to shore-up medical supply chains
In a recent strategy to combat rising inflation and the cost of living crisis, President Joe Biden has invoked a Cold War-era act to increase investment in a selection of medicines and supplies. -
News Women in Pharma: Delivering solutions for gender diversity
In our new monthly series, we interview women from across the pharmaceutical industry and supply chain to discuss the importance of gender diversity in healthcare, the workplace, and beyond. -
News CPHI Barcelona Speaker Interview – What the US FDA’s Quality Management Maturity Means for the Pharma Industry
At CPHI Barcelona (24–26 October, 2023), we spoke to Sireesha Yadlapalli, CEO of Pharmatech Associates, who gave a presentation on the implications of the US FDA’s Quality Management Maturity (QMM) Initiative, and spoke on the panel of the ... -
News CPHI Podcast Series: What does the changing US Pharma market mean for industry and patients alike?
In this week's episode of the CPHI Podcast Series Lucy Chard, Digital Editor for CPHI Online is joined by James Manser to discuss the political and market changes in the US pharma field. -
News Wegovy and weight-loss drugs driving demand for manufacturers that can fill syringes
Injectable weight-loss treatments are prompting contract manufacturers to invest and include fill-finish services into their service portfolios, in a bid to attract pharmaceutical giants developing drugs similar to Novo Nordisk's Wegovy.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance